Cadrenal Therapeutics Appoints Dr. Lee Scott Golden to Board, Enhancing Anticoagulation Development
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Dec 01 2025
0mins
Source: Newsfilter
- New Board Member: Cadrenal Therapeutics appoints Dr. Lee Scott Golden as an independent director effective immediately, aiming to leverage his extensive experience in cardiovascular medicine and anticoagulation to drive the company's strategy.
- Clinical Development Expertise: Dr. Golden, serving as Chief Medical Officer at PTC Therapeutics, oversees global clinical development, which is expected to provide crucial guidance for the advancement of Cadrenal's tecarfarin and broader pipeline.
- Industry Background: With over 25 years in the pharmaceutical industry, including senior roles at Pfizer, Dr. Golden brings valuable insights for managing strategic clinical development plans at Cadrenal.
- Market Potential: Cadrenal focuses on developing novel anticoagulants to bridge critical gaps in current therapies, which is anticipated to significantly improve treatment outcomes for patients with complex cardiovascular conditions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CVKD?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CVKD
Wall Street analysts forecast CVKD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CVKD is 45.00 USD with a low forecast of 45.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 7.460
Low
45.00
Averages
45.00
High
45.00
Current: 7.460
Low
45.00
Averages
45.00
High
45.00
No data
About CVKD
Cadrenal Therapeutics, Inc. is a biopharmaceutical company developing therapeutics to overcome the limitations of anticoagulation therapy. It has three clinical-stage assets: VLX-1005, a first-in-class Phase 2 12-LOX Inhibitor for patients with HIT; tecarfarin, an oral vitamin K antagonist (VKA) for chronic use in patients with kidney dysfunction or left ventricular assist devices (LVADs), and frunexian, a parenteral small-molecule Factor XIa antagonist for use in acute hospital settings. Its product candidate, tecarfarin, is a late-stage, reversible oral VKA in the same drug class as warfarin, designed to prevent heart attacks, strokes, and deaths due to blood clots in patients requiring chronic anticoagulation. Its frunexian is a small molecule fast-on, fast-off parenteral Phase II-ready potent intravenous (IV) Factor XIa inhibitor designed for acute care settings, especially where contact activation of coagulation by medical devices or artificial surfaces plays a significant role.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cadrenal Advances Anticoagulation Pipeline, VLX-1005 Completes Phase 2 Trial
- Phase 2 Trial Progress: Cadrenal's anticoagulant drug VLX-1005 has completed its Phase 2 clinical trial, with data currently under analysis and expected to be published soon, indicating the company's potential in the anticoagulation sector despite a 4% drop in stock price prior to this announcement.
- FDA Fast Track Designation: VLX-1005 has received both Orphan Drug and Fast Track designations from the FDA, highlighting its potential market value in treating heparin-induced thrombocytopenia (HIT) and likely expediting subsequent regulatory approval processes.
- Market Demand Insight: Approximately 50,000 new HIT cases occur annually in the U.S., underscoring the urgent need for new therapies, with Cadrenal's product poised to fill gaps left by existing anticoagulants, particularly in the context of heparin use during cardiovascular surgeries.
- Other Development Programs: In addition to VLX-1005, Cadrenal is advancing Tecarfarin and Fruinexian, with the former targeting patients with end-stage kidney disease and the latter being a short-acting Factor XI inhibitor for cardiovascular surgery, demonstrating the company's diversified strategic approach in the anticoagulation field.
Continue Reading
Cadrenal Acquires VLX-1005 to Strengthen Anticoagulation Pipeline
- Acquisition Strengthens Pipeline: Cadrenal Therapeutics' acquisition of VLX-1005 and related 12-LOX assets immediately enhances its pipeline, addressing a $40 billion anticoagulation market and approximately 56,000 annual HIT diagnoses.
- Optimistic Clinical Outlook: VLX-1005 demonstrated good tolerability in two Phase 1 studies with healthy participants, showing no deaths or serious adverse events, indicating promising potential for application in HIT patients.
- Significant Market Potential: The HIT market is projected to reach $1 billion in the US and EU, and the development of VLX-1005 will help improve patient outcomes, addressing urgent needs in high-risk populations.
- Strategic Investment Returns: The acquisition agreement includes milestone payments and royalties on global sales, ensuring Cadrenal can allocate capital to advance VLX-1005's clinical development, driving long-term growth for the company.
Continue Reading